Prognostic biomarkers in MCL: insights from the SHINE trial on the impact of MCL35 score and TP53 mutation status

ABSTRACT: The MCL35 gene expression assay encompasses key risk features and stratified older patients with mantle cell lymphoma (MCL) using routine biopsies. In the SHINE trial, high-risk patients had poor outcomes despite adding ibrutinib to bendamustine-rituximab, highlighting an urgent need for novel strategies in high-risk MCL.